Helus Pharma is a clinical-stage pharmaceutical company developing psychedelic-inspired medicines for mental health. The company is pre-revenue and focuses entirely on R&D. Helus Pharma uses deuteration—a chemical modification replacing hydrogen atoms with deuterium—to improve pharmacokinetic properties by slowing metabolism to produce more predictable effects. The core program, HLP003, is an oral psilocin analog developed as an adjunctive treatment for major depressive disorder and has FDA Breakthrough Therapy Designation. HLP003 is currently in Phase 3 trials. A second program, HLP004, is a deuterated version of DMT delivered via intramuscular injection as an adjunctive treatment for generalized anxiety disorder. HLP004 is designed to provide a shorter therapeutic session than standard psychedelics to improve clinic efficiency. Helus Pharma also maintains a preclinical portfolio of phenethylamine and tryptamine derivatives. Helus Pharma targets patients with moderate-to-severe conditions who are inadequately controlled by standard therapies. The business model involves selling prescription medicines through interventional psychiatry clinics, utilizing an infrastructure similar to existing ketamine infusion models. Helus Pharma outsources manufacturing and clinical trial management to third-party providers and relies on equity and debt financing to fund operations while seeking regulatory approvals.